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Theresa Watson,1 David MacDonald,2 Xiaoyan Song,3,4 Kira Bromwich,3 Joseph Campos,4,5
Jane Sande,1 Roberta L. DeBiasi3,4Adenovirus (AdV) infections are a major cause of morbidity and mortality in patients undergoing hematopoi-
etic stem cell transplantation (HSCT). To evaluate the use of molecular AdV testing in HSCTat our institution
and identify risk factors for AdV viremia and disease, we performed a retrospective cohort study of all HSCT
recipientswhohad undergoneAdVpolymerase chain reaction testing over a 2-year period. Twocohortswere
identified: cohort 1, comprising patients testing positive for AdV (n 5 7) and cohort 2, comprising patients
testing negative (n 5 36). Overall patient characteristics were not statistically significantly different be-
tween the 2 cohorts. A comparison of cohort 1 and cohort 2 identified the following medication ex-
posures as risk factors influencing AdV status: preparatory regimens using fludarabine (relative risk [RR],
8.73; 95% confidence interval [CI], 1.18-64.27; P 5 .006), melphalan (RR, 3.47; 95% CI, 0.76-15.94: P 5
.08), and/or cyclophosphamide (RR, 0.18; 95% CI, 0.02-1.4; P 5 .05), and GVHD prophylaxis with methyl-
prednisone (RR, 3.73; 95% CI, 1.01-13.9; P 5 .04). AdV-positive patients had higher grades of GVHD
and higher rates of GVHD of the gastrointestinal tract (RR, 4; 95% CI, 1.18-13.5; P 5 .03) compared with
AdV-negative patients. Four of the 7 AdV-positive patients had concomitant clinical manifestations of disease,
including pneumonia, diarrhea, and/or disseminated disease. Clinical outcomes in symptomatic patients
included resolutionof disease in 2 patients and death in 2 patients. All 7AdV-positive patients received antiviral
therapy, including 1 patient with severe disseminated disease that resolved after administration of liposomal
cidofovir. Our study at a large pediatric HSCT center provides important preliminary data for the develop-
ment of a prospective trial destined to identify specific HCST patient subpopulations that might benefit
most from molecular screening and early preemptive therapy.
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Adenovirus (AdV) is an important cause of
morbidity and mortality in patients undergoing hema-
topoietic stemcell transplantation (HSCT), particularly
in pediatric patients [1,2]. The reported incidence of
AdV infection in HSCT recipients ranges from 5%
to 47% [3,4], with 29% to 75% of infected patients
manifesting disease symptoms that can be attributed
to AdV infection [5,6]. Previous studies in pediatric
bone marrow transplantation recipients have shown
AdV infection in 6% to 46% of patients [7,8]. Up to
82% of those with AdV detected in peripheral blood
samples do not survive [9].
AdV polymerase chain reaction (PCR) can be used
to detect viral DNA in whole blood, plasma, urine,
stool, conjunctiva, and broncheoalveolar lavage speci-
mens [3,10-13]. Adenoviral DNA has been detected in
stool and urine preceding disseminated infection
[10,11]. DNA levels .1  106/g of stool have been1227
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tween a specific peripheral blood DNA copy number
and clinical disease or mortality has been shown; how-
ever, rising viral peripheral blood DNA levels have
been associated with increased mortality, suggesting
that a threshold may exist [4,14].
Clinical manifestations of AdV in HSCT recipi-
ents include upper and lower respiratory tract diseases,
hepatitis, genitourinary tract diseases, gastrointestinal
(GI) diseases, central nervous system diseases, and dis-
seminated diseases. Diarrhea is the most common
presentation of AdV disease [1,4]. Hemorrhagic
cystitis and AdV DNA in stool have been shown to
precede the onset of disseminated disease [4,11].
Clinical diagnosis of AdV disease can be delayed
because of the variable clinical presentations and the
complicated clinical picture post-HSCT, including
graft-versus-host disease (GVHD) [15]. However,
PCR positivity in blood precedes clinical symptoms
by a median of 3 weeks and presents a potential oppor-
tunity to intervene with the goal of improving out-
comes [9,15].
Multiple groups have attempted to identify
specific risk factors for infection and/or disease to
identify populations at greatest risk for poor outcome
[16,17]. Published risk factors for AdV infection
include younger age, GVHD, second HSCT, allo-
geneic transplantation, T cell depletion, unrelated or
mismatched grafts, total body irradiation (TBI),
lymphopenia, bone marrow as the stem cell source,
and myelodysplastic syndrome as indications for
transplantation [16,18]. Known risk factors for
disseminated disease include the number of sites of
AdV detection, immunosuppressive therapy, lympho-
cytopenia, and detection of rising AdV viral load in
blood [2,4,12].
The currently available antiviral therapy for AdV
infection is i.v. cidofovir, which has substantial toxic-
ities, including nephrotoxicity, bone marrow suppres-
sion, and electrolyte disarray, limiting its clinical
utility in asymptomatically infected patients [6,19].
An algorithm for testing and treatment has been
published for application to a pediatric HSCT
population; however, the intervention studied was i.v.
cidofovir [17]. Newer therapies with efficacy against
AdV but lower toxicity, such as lipophilic cidofovir
(CMX001), are in development and have been used an-
ecdotally in the setting of AdV disease in HSCT recip-
ients [2]. In addition, cytotoxic T lymphocyte infusion
has shown effectiveness in treating patients with AdV
disease [14,20,21]. A strategy incorporating the use of
newer, less toxic therapies may allow treatment of
a broader group of patients at risk for disease.
The availability of less toxic therapies, in conjunc-
tion with the increasingly widespread availability of
PCR, has the potential to improve morbidity and mor-
tality related to AdV disease in the HSCT population.However, many areas of uncertainty remain, including
the selection of specific patient subpopulations at
greatest risk for severe disease, the potential safety
and efficacy of prophylaxis, the role of prospective
screening with potential preemptive therapy, and the
determination of a viral load cutoff that is predictive
of disease development.
In the present retrospective cohort study over
a 2-year period at our institution, we identified risk fac-
tors predictive of AdV infection in pediatric HSCT
recipients.METHODS
Quantitative real-time AdV PCR testing was per-
formed at Viracor-IBT Laboratories (Lee’s Summit,
MO). The assay was designed to detect all 52 serotypes
of AdV and had a lower limit of detection of 100 AdV
DNA copies/mL.
Between May 2008 and April 2010, 185 pediatric
patients who had undergone quantitative AdV PCR
testing were retrospectively identified from the Chil-
dren’s National Medical Center clinical microbiology
laboratory database. Forty-eight of these 185 patients
had undergone HSCT, 42 of whom had complete
medical records available for review and were included
in this study. AdV testing during this period was per-
formed before the implementation of routine AdV
PCR screening in this patient population. The vast
majority of subjects (33 of 42; 79%) underwent testing
based solely on clinical suspicion. Sources tested in
symptomatic patients included blood, stool, urine,
broncheoalveolar lavage, and/or sputum specimens,
depending on clinical symptomatology. A much
smaller subset of subjects (9 of 42; 21%) was tested
as part of routine screening (of blood specimens) insti-
tuted at the discretion of specific attending physicians.
A data extraction tool was developed and applied
systematically to assess all 42 patient records. Factors
assessed included underlying diagnosis, type of stem
cell transplantation (including HLA match and stem
cell source), preparative regimen, GVHD prophylaxis,
date of engraftment, surveillance for other viruses (ie,
Epstein-Barr virus, cytomegalovirus, herpes simplex
virus, varicella-zoster virus, BK virus, and human
herpsesvirus-6), antiviral therapies used for prophy-
laxis or treatment, post-transplantation complications,
and GVHD status (presence, type, and severity). Spe-
cific information on each patient’s AdV status was
documented as well, including the number of AdV
PCRs performed, time fromHSCT to the first positive
PCR, duration of AdV positivity, peak viral load,
absolute neutrophil count (ANC) and absolute lym-
phocyte count (ALC) at time of peak viral load, time
to recovery of ALC .500, clinical presentation
(when applicable), treatment course, and outcome.
Table 1. Patient Characteristics
Cohort 1
(AdV-Positive)
Cohort 2
(AdV-Negative) P value
Number of patients 7 36
Mean age, years 7 9.14
0-4 57% 31% .55
5-12 14% 34%
13-18 29% 34%
Male sex 57% 69%
Pretransplantation diagnosis
Hematologic 43% 31% .39
Immunologic 29% 14%
Malignant 29% 54%
Donor HLA match
MUD 86% 60% .21
MRD 14% 29% .45
Autologous 0% 11% .35
6/6, 8/8, or 10/10 match 57% 51% .83
Less than 6/6, 8/8,
or 10/10 match
43% 49% .83
Stem cell source
Bone marrow 57% 51% .97
Peripheral blood stem cells 14% 14%
Cord blood 29% 34%
Preparatory regimen
Myeloablative 14% 51% .06
Nonmyeloablative 86% 49%
Viral prophylaxis
None 57% 54% .94
Acyclovir 29% 26%
Valacyclovir 14% 20%
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database for analysis.
Two patient cohorts were identified: cohort 1,
comprising patients who tested positive for AdV
(n 5 7) and cohort 2, comprising patients who tested
negative (n 5 35). Clinical data were collected from
all 42 patients and entered into the electronic database
for analysis.
Patients testing positive for AdV (termed ‘‘infec-
tion’’) were further categorized into 2 groups: asymp-
tomatic patients with no clinical evidence of disease
and symptomatic patients (termed ‘‘disease’’) with
clinical manifestations of infection, such as fever, diar-
rhea, respiratory symptoms, or disseminated disease.
Statistical analysis included unadjusted and ad-
justed logistic regression analysis to identify factors
predicting AdV positivity. Unadjusted categorical
variables including sex, underlying diseases, and type
of stem cell transplantation were compared using the
c2 test. We also compared continuous variables, such
as length of AdV positivity, using the nonparametric
method. A separate risk analysis for subjects tested
due to clinical symptoms (the vast majority) rather
than routine screening was not possible, because of
small sample size. A P value \ .05 was considered
statistically significant.RESULTS
Overall patient characteristics were not statistically
differentbetween the2 cohorts (Table 1).AdV infection
was detected in 7 of 42 HSCT recipients (16.6%; 3 fe-
males and 4 males). The median age of AdV-infected
patients at the time of HSCT was 7 years (range, 0-17
years). Underlying diagnoses included relapsed acute
myelogenous leukemia, secondary myelodysplastic
syndrome, b-thalassemia, congenital amegakaryocytic
thrombocytopenia, severe aplastic anemia, and severe
combined immunodeficiency disease.
The vast majority of the patients (33 of 42; 79%)
received testing based only on clinical suspicion. In
these patients, the most common symptom prompting
testing was unexplained fever, and additional clinical
symptoms prompting testing included rash, respira-
tory distress, GI symptoms, prolonged myelosuppres-
sion, hypotension, or sepsis syndrome. Thirty of the 33
patients (91%) tested in this manner were found to be
AdV-negative, and 3 (9%) were AdV-positive. The
clinical symptoms prompting testing in these 3 pa-
tients were diarrhea, fever with prolonged myelosup-
pression, and pneumonia.
A much smaller subset of patients (9 of 42; 21%)
were tested as part of routine screening, instituted at
the discretion of specific attending physicians. For
these 9 patients, testing was initiated on posttransplan-
tation day 0 to112, themajority in the first 7 days aftertransplantation. Five of the 9 patients undergoing rou-
tine screening (56%) were AdV-negative, and the
other 4 (44%) were AdV-positive. Although our sam-
ple size is small, the proportion of patients testing pos-
itive using this strategy was much higher than that
testing positive based only on clinical suspicion (44%
versus 9%).
Preparative regimens containing the following
medications were identified as risk factors influencing
AdV status (cohort 1 compared with cohort 2): fludar-
abine (relative risk [RR], 8.73; 95% confidence interval
[CI], 1.18-64.27; P5 .006), melphalan (RR, 3.47; 95%
CI, 0.76-15.94; P 5 .08), and/or cyclophosphamide
(RR, 0.18; 95% CI, 0.02-1.4; P5 .05) (Table 2). Med-
ications not associated with statistically significant
increased risk for the development of AdV infection in-
cluded alemtuzumab (RR, 2.17; 95% CI, 0.56-8.45;
P 5 .26), busulfan (RR, 0.45; 95% CI, 0.06-3.19;
P 5 .39), TBI (RR, 0.42; 95% CI, 0.06-3.10; P 5 .36),
etoposide (RR, 1.31; 95% CI, 0.22-8.01; P 5 .77),
carboplatin (RR, 1; 95% CI, 0.16-6.6; P 5 .98),
thiotepa (RR, 1; 95% CI, 0.16-6.6; P 5 .98), and
antithymocyte globulin (ATG) (RR, 0.37; 95% CI,
0.05-2.78; P 5 .30).
Additional analysis of risk in the context of specific
combination preparative regimens was attempted for
the 13 different combinations of preparative regimens
used in the patients included in this study. The largest
number of patients received fludarabine/melphalan/
campath (cohort 1, n 5 11; cohort 2, n 5 4) and
Table 2. Relative Risks Associated with Preparatory Agent and GVHD Prophylaxis Drug Exposure
Cohort 1 (AdV-Positive) Cohort 2 (AdV-Negative) RR 95% CI P value
Preparatory regimen
Alemtuzumab 4 12 2.17 0.56-8.45 .26
Fludarabine 7 13 8.73 1.18-64.27 .006
Melphalan 5 13 3.47 0.76-15.94 .08
Busulfan 0 8 0.45 0.06-3.19 .39
Cyclophosphamide 1 19 0.18 0.02-1.40 .05
TBI 1 11 0.42 0.06-3.10 .36
Etoposide 0 2 1.31 0.22-8.01 .77
Carboplatin 0 3 1 0.16-6.6 .98
Thiotepa 0 3 1 0.16-6.6 .98
ATG 1 12 0.37 0.05-2.78 .30
GVHD prophylaxis
Cyclosporine 7 30 0.62 0.11-3.42 .60
Tacrolimus 0 2 1.18 0.02-7.22 .85
Sirolimus 0 1 1.63 0.29-9.0 .60
Mycophenolate mofetil 1 6 0.74 0.10-5.20 .75
Methylprednisone 4 6 3.73 1.01-13.9 .04
Methotrexate 4 20 0.78 0.20-2.98 .71
Figure 1. Sites of GVHD. Cohort 1 (AdV-positive) patients are
depicted in black; cohort 2 (AdV-negative) patients, in gray.
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cohort 2, n 5 0). We did not detect a statistically sig-
nificant difference with regard to receipt of either
regimen and risk for AdV positivity (P5 .18 for fludar-
abine/melphalan/campath; P 5 .13 for cyclophospha-
mide/TBI). For the other 11 combination regimens,
there were not adequate numbers of patients to pro-
vide sufficient power for risk analysis between cohorts.
GVHD prophylaxis with methylprednisone was
associated with an increased risk of AdV infection
(RR, 3.73; 95%CI, 1.01-13.9; P5 .04). Other medica-
tions used for GVHD prophylaxis included cyclospor-
ine (RR, 0.62; 95%CI, 0.11-3.42; P5 .60), tacrolimus
(RR, 1.18; 95% CI, 0.02-7.22; P 5 .85), mycopheno-
late mofetil (RR, 0.74; 95% CI, 0.10-5.2; P 5 .75),
sirolimus (RR, 1.63; 95% CI, 0.29-9.0; P 5 .60),
ATG (RR, 0.37; 95% CI, 0.05-2.78; P 5 .30), and
methotrexate (RR, 0.78; 95% CI, 0.2-2.98; P 5 .71),
none of which showed increased risk for development
of AdV infection. Compared with AdV-negative pa-
tients, AdV-positive patients had significantly higher
GVHD grades with higher rates of GVHD of the GI
tract (RR, 4; 95% CI, 1.18-13.5; P 5 .03) (Figure 1).
Other variables assessed that were not associated
with a statistically significant increase in risk for AdV
infection included stem cell source (matched unrelated
donor [MUD; RR, 3.33; 95%CI, 0.44-25.15; P5 .19],
matched related donor [MRD; RR, 0.47; 95% CI,
0.06-3.48; P 5 .43], autologous transplantation [RR,
0.83; 95% CI, 0.13-5.54; P 5 .85]), HLA testing,
and underlying disease (hematologic [RR, 1.5; 95%
CI, 0.39-5.8; P 5 .56], immunologic [RR, 2; 95%
CI, 0.48-8.32; P 5 .35], malignant [RR. 0.4; 95% CI,
0.09-1.84; P5 .21]) (Table 1). However, 5 of the 7 pa-
tients who developed AdV infection had a nonmalig-
nant disorder as the underlying diagnosis.
The concomitant use of antiviral therapies, such as
acyclovir and ganciclovir, for herpes simplex virusand/or cytomegalovirus prophylaxis was not associ-
ated with altered risk of AdV positivity or disease
(data not shown).
Four of the 7 AdV-positive patients (57%) had
concomitant clinical manifestations of disease, includ-
ing pneumonia, diarrhea, and/or disseminated disease.
Clinical outcomes in the symptomatic patients in-
cluded resolution of disease in 2 patients and death
in 2 patients, with concomitant bacterial sepsis in 1 pa-
tient. Peak viral load was not predictive development
of disease or severity (Table 3).
In the 7 AdV-positive patients, AdV was first
detected between day10 and day1350 posttransplan-
tation, with detection within the first 18 days post-
transplantation in 6 of the 7 patients. The duration
of documented AdV viremia in the AdV-positive pa-
tients ranged from 12 to 108 days.
The ALC coinciding with peak viral load in these
patients ranged from 0-1130, with a mean of 310. Be-
cause the majority of patients developed AdV viremia
in the first 18 days posttransplantation, we compared
Table 3. Clinical and Virologic Features of Patients with Detectable AdV
Patient
Age
at SCT,
Years Sex
Reason
for AdV
Testing
Clinical AdV
Disease
Underlying
Diagnosis Treatment Conditioning
Peak Viral
Load
Day of First
Positive
AdV PCR
Relative to
Transplantation
Days to
Engraftment
ALC at
Peak Viral
Load
Days to
ALC
Recovery
(>500) Antiviral Therapy Outcome
1 13 F Clinical Diarrhea Idiopathic
aplastic
anemia
BMT MUD
9/10
Fludarabine, melphalan,
campath
6.80E+08 77 13 140 24 Cidofovir i.v.,
cidofovir p.o.
(liposomal)
Resolved
2 0.4 M Screen Diarrhea SCID BMT
MRD
10/10
Fludarabine, ATG 1.51E+04 221 18 1130 17 Cidofovir i.v. Resolved
3 11 M Clinical Pneumonia AML with
secondary
MDS
PBSCT
MUD
10/10
Fludarabine, melphalan 4.20E+07 347 11 710 13 Cidofovir i.v.,
ribavirin,
foscarnet,
ganciclovir
Death
4 3 M Screen Respiratory distress SCID Cord blood
MUD
7/8
Fludarabine, melphalan,
campath
1.10E+05 217 NA 370 Did not
recover
Cidofovir i.v. Death (concomitant
bacterial sepsis)
5 17 F Clinical Fever;
myelosuppression
Relapsed AML Cord blood
MUD 4/6
Fludarabine, cytarabine,
TBI
9.75E+04 53 48 0 86 Cidofovir i.v.,
foscarnet
Resolved
6 1 M Screen None CAMT BMT
MUD
10/10
Fludarabine, melphalan,
campath
6.30E+06 19 14 40 82 Cidofovir i.v. Resolved
7 3 F Screen None b-thalassemia BMT
MUD
10/10
Fludarabine, melphalan,
campath
2.20E+03 12 14 90 22 Ganciclovir,
foscarnet
Resolved
AML indicates acute myelogenous leukemia; BMT, bone marrow transplantation; CAMT, congenital amegakaryocytic thrombocytopenia; MDS, myelodysplastic syndrome; NA, not applicable; PBSCT, peripheral blood
stem cell transplantation; SCID, severe combined immunodeficiency.
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posttransplantation, as well as the mean number of
days to recovery of ALC .500, between cohorts.
Three of the 35 patients (9%) in the AdV-negative co-
hort and 1 of 7 (14%) in the AdV-positive cohort never
achieved an ALC.500. In the remaining 38 patients,
there was a non statistically significant trend toward
shorter time to recovery of ALC for the AdV-
negative cohort compared with the AdV-positive co-
hort (26.3 6 14.3 days versus 40.7 6 33.9 days; P 5
.08). There was no significant difference between co-
horts in terms of minimum or maximum ALC in the
first 18 days posttransplantation (mean minimum
ALC, 17 6 15 for cohort 1 versus ALC, 14 6 13 for
cohort 2 [P 5 .70]; mean peak ALC, 579 6 795 for
cohort 1 versus ALC, 430 6 370 for cohort 2
[P 5 .60]).DISCUSSION
This retrospective study at a large pediatric HSCT
center confirms and expands on potential risk factors
for AdV infection that have been identified in previous
smaller studies in adults and mixed-age populations.
Previously identified risk factors include age, T cell de-
pletion, MUD stem cell source, HLA mismatch, pres-
ence of GVHD, immunosuppressive conditioning
regimens, and use of steroids [3,9,12,22].
In this study, fludarabine andmelphalan were asso-
ciated with an increased risk of AdV viremia. Both of
these drugs are known to result in slower lymphocyte
recovery rates, leading to increased risk for viral infec-
tions. The increased risk of AdV infection in patients
receiving these 2 drugs could also be associated with
their use in combination with alemtuzumab, possibly
acting as surrogates for alemtuzumab use. Although
the use of alemtuzumab for T cell depletion has been
associated with increased risk of AdV viremia in several
other studies, the present study found no altered risk
for patients who received this immunosuppressive
agent or for those who received ATG.
GVHD prophylaxis with steroids was significantly
associated with increased risk of AdV viremia in our
patient population. This is likely secondary to the
cell-mediated immunosuppressive nature of steroids,
which is not characteristic of other GVHD prophylac-
tic medications. Patients with GVHD of the GI tract
also had an increased incidence of AdV infection.
Given that the GI tract is a preferential target of
AdV infection, damaged intestinal mucosa resulting
from GVHD likely increases the infectivity of AdV,
leading to more disseminated disease in these patients.
The present study did not find an increased risk of
AdV infection associated with stem cell source (MRD
or MUD), in disagreement with previous studies
[4,10,17,19]. It is important to note, however, thatonly 1 of our 7 AdV-positive patients received
an MRD transplantation and had a fludarabine-
containing conditioning regimen. This might have af-
fected our results, as might have our small sample size.
In our study population, 16% of the patients who
underwent AdV PCR testing had detectable AdV
viremia. This rate is consistent with previous studies
in pediatric bone marrow transplantation recipients in
which 6% to 46% of patients had detectable AdV
[4,23]. Of our patients with detectable AdV
viremia, 57% had associated clinical symptoms, again
consistent with previous studies in which 29% to 75%
of patients with infection manifested disease that
could be attributed to AdV [1,4,23]. It is often difficult
to definitively attribute symptoms to a specific cause
in these critically ill patients, given the high
correlation among GVHD, AdV infection, and other
transplantation-related illnesses. In the past, AdV was
detected primarily by culture. As the use of molecular
detection methods becomes more widely available,
this wide variation in infection and disease rates may
be retrospectively attributed to differences in sensitivity
of detection techniques.
The most common clinical presentation of AdV
disease reported in several studies is diarrhea [1,3].
Only 2 of our 7 patients with detectable AdV had
diarrhea, which resolved after treatment with
cidofovir (i.v. and oral). Two of the patients in our
population died, yielding an observed mortality rate
of 40%. Both of these patients had respiratory
symptoms as the primary manifestation of AdV
disease and received appropriate antiviral therapy.
This 40% mortality rate is consistent with previous
studies in pediatric populations; however, no other
study has reported an increased risk of death in the
setting of respiratory illness. It is possible that AdV
disease in the lung is more refractory to treatment.
We could not demonstrate any association be-
tween peak viral load and the likelihood of developing
symptomatic disease and/or death. Although rising ad-
enoviral titers and AdV viremia have been identified as
risk factors for disseminated disease, a clinically useful
cutoff at which treatment should be initiated has not
yet been identified. Interpreting a positive AdV PCR
remains difficult in the setting of equivocal clinical
findings. In a recent retrospective study of pediatric
HSCT recipients, AdV was detected in 11 of 26 pa-
tients (42%). Seven of these patients were able to clear
the virus without intervention. All 5 patients with a
viral load\2 106 cleared the infection without treat-
ment [24]. In the present study, 4 of the 7 AdV-positive
patients had an adenoviral load\2  106, and all 4 of
these patients received therapy with efficacy against
AdV. Despite this treatment, 1 of the 4 patients with
an adenoviral load\2  106 died. In another study,
the prevalence of disseminated disease was 37%,
with a mortality rate of 25% in this subset of patients.
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viral load exceeded 104/mL [10]. However, these pa-
tients were treated with cidofovir immediately on de-
tection of AdV, and viral loads might have increased
without intervention. Given the wide variation in ob-
served viral loads in these studies, as well as the poten-
tial toxicity of effective treatment, further study of the
clinical significance of AdV viral load is needed.
We were interested in assessing whether ALC was
an independent risk factor associated with AdV vire-
mia in this patient population. Themajority of patients
with detectable AdV exhibited positivity within the
first 18 days posttransplantation, a time at which there
were no appreciable differences in either minimum or
maximum ALC between the 2 cohorts. This finding
suggests that ALC is not an independent risk factor
for developing AdV viremia. However, we did detect
a non statistically significant trend for shorter time to
recovery of ALC for the AdV-negative cohort com-
pared with the AdV-positive cohort (26.3 days versus
40.3 days), raising the possibility that AdV viremia
might predispose to a longer period for recovery of
ALC, with the concomitant increased risk of other
opportunistic infections.
Our study, like others preceding it, is limited by its
relatively small sample size and retrospective design,
which are potentially prone to bias, making compari-
son across studies difficult. A prospective study would
remove any potential bias of the results, and a multi-
center design would markedly increase that sample
size. An additional limitation is the fact that the major-
ity (79%) of patients in our study underwent AdV test-
ing before the development of a systematic prospective
monitoring procedure. For this reason, the indications
for testing were based on individual physician discre-
tion. Characterization of the patient characteristics
and clinical factors present at the time of testing did
not identify any obvious differences between patients
tested due to clinical symptoms versus those tested
during routine screening. However, the fact that the
proportion of patients testing positive using the
screening strategy (4 of 9; 44%) was much higher
than that testing positive based only on clinical suspi-
cion (3 of 33; 9%) suggests that some patients with
asymptomatic AdV viremia likely were not identified
in the symptom-based testing cohort.
A larger, multicenter prospective studymonitoring
AdV load posttransplantation is warranted, particu-
larly as more viable treatment options with less poten-
tial toxicity (eg, CMX-001) become available for
treating patients with AdV viremia and disease. It is
possible that in a larger study, viral load could be a use-
ful marker for predicting outcome for infected patients
and/or for selecting cutoffs for preemptive therapy in
asymptomatic infected patients. Such a trial would al-
low for identification of patient subpopulations at
greatest risk for AdV disease that might warrant fre-quent molecular screening and benefit most from pro-
phylactic and/or preemptive treatment. A future study
could also include pretransplantation AdV serostatus
and/or viral load to evaluate the frequency and role
of primary infection versus reactivation, as well as the
implications of pretransplantation status on clinical
manifestations, morbidity, and mortality.
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